Innovent Annouces Multiple Clinical Study Results of Mazdutide to be Presented at the EASD 2024
Innovent Biologics announces mazdutide clinical study results to be presented at EASD 60th Annual Meeting in Madrid, including Phase 3 DREAMS-2 study in type 2 diabetes. Mazdutide, a GLP-1R/GCGR dual agonist, shows superior blood sugar-lowering and weight loss efficacy. Innovent has two NDAs accepted by China's NMPA for review and five ongoing Phase 3 studies.
Related Clinical Trials
Highlighted Terms
Related News
Innovent Biologics announces mazdutide clinical study results to be presented at EASD 60th Annual Meeting in Madrid, including Phase 3 DREAMS-2 study in type 2 diabetes. Mazdutide, a GLP-1R/GCGR dual agonist, shows superior blood sugar-lowering and weight loss efficacy. Innovent has two NDAs accepted by China's NMPA for review and five ongoing Phase 3 studies.
Innovent Biologics announces multiple mazdutide clinical study results to be presented at EASD 60th Annual Meeting in Madrid, including Phase 3 DREAMS-2 study in Chinese adults with type 2 diabetes. Mazdutide, a GLP-1R/GCGR dual agonist, shows superior blood sugar-lowering and weight loss efficacy. Innovent, founded in 2011, develops high-quality medicines for various diseases.
Innovent Biologics presented Phase III trial data on mazdutide, showing it superior to Eli Lilly's Trulicity in diabetes management and significant weight reduction in obese patients at EASD. Mazdutide, a dual GLP-1 and GCGR agonist, demonstrated improvements in cardiovascular and kidney functions, and liver fat content reduction.
Innovent Biologics to present multiple mazdutide clinical study results at EASD 60th Annual Meeting in Madrid, including Phase 3 DREAMS-2 study in Chinese adults with type 2 diabetes. Mazdutide, a GLP-1R/GCGR dual agonist, shows superior blood sugar-lowering and weight loss efficacy. Innovent has two NDAs accepted by China's NMPA for review and five ongoing Phase 3 studies.
Innovent Biologics announces Phase 3 results for mazdutide, a GLP-1R/GCGR dual agonist, showing superiority to dulaglutide in glycemic control and weight loss in Chinese T2D patients. Mazdutide also improves cardiometabolic risk factors and has a favorable safety profile. Two NDAs for mazdutide are under review in China.
Innovent Biologics to present multiple mazdutide clinical study results at EASD 60th Annual Meeting in Madrid, including Phase 3 DREAMS-2 study in Chinese adults with type 2 diabetes. Mazdutide, a GLP-1R/GCGR dual agonist, shows superior blood sugar-lowering and weight loss efficacy. Innovent has two NDAs accepted by China's NMPA for review and five ongoing Phase 3 studies.